Wave Life Sciences Ltd (NASDAQ:WVE) has a beta value of -0.94 and has seen 0.43 million shares traded in the recent trading session. The company, currently valued at $1.23B, closed the recent trade at $8.03 per share which meant it lost -$0.05 on the day or -0.56% during that session. The WVE stock price is -108.47% off its 52-week high price of $16.74 and 47.07% above the 52-week low of $4.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.4 million shares traded. The 3-month trading volume is 1.04 million shares.
The consensus among analysts is that Wave Life Sciences Ltd (WVE) is Buy stock at the moment, with a recommendation rating of 1.18. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.25.
Wave Life Sciences Ltd (NASDAQ:WVE) trade information
Sporting -0.56% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the WVE stock price touched $8.03 or saw a rise of 26.4%. Year-to-date, Wave Life Sciences Ltd shares have moved -35.04%, while the 5-day performance has seen it change -14.88%. Over the past 30 days, the shares of Wave Life Sciences Ltd (NASDAQ:WVE) have changed -20.05%. Short interest in the company has seen 8.34 million shares shorted with days to cover at 7.26.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 63.5% from the levels at last check today. The projected low price target is $15.0 while the price target rests at a high of $36.0. In that case, then, we find that the latest price level in today’s session is -348.32% off the targeted high while a plunge would see the stock gain -86.8% from the levels at last check today.
Wave Life Sciences Ltd (WVE) estimates and forecasts
The company’s shares have lost -3.08% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -34.15%.
9 analysts offering their estimates for the company have set an average revenue estimate of 11.28M for the current quarter. 8 have an estimated revenue figure of 14.81M for the next ending quarter. Year-ago sales stood 12.54M and 19.69M respectively for this quarter and the next, and analysts expect sales will shrink by -10.06% for the current quarter and -34.15% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 34.27% over the past 5 years. Earnings growth for 2025 is a modest -36.01% while over the next 5 years, the company’s earnings are expected to increase by 6.79%.
WVE Dividends
Wave Life Sciences Ltd is expected to release its next earnings report on 2025-Mar-03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Wave Life Sciences Ltd (NASDAQ:WVE)’s Major holders
Insiders own 16.53% of the company shares, while shares held by institutions stand at 83.49% with a share float percentage of 100.03%. Investors are also buoyed by the number of investors in a company, with Wave Life Sciences Ltd having a total of 243.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 18.2 million shares worth more than $90.83 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 14.0527% of shares outstanding.
The other major institutional holder is MAVERICK CAPITAL LTD, with the holding of over 7.67 million shares as of 2024-06-30. The firm’s total holdings are worth over $38.27 million and represent 5.9211% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 1.60% shares in the company for having 2.45 shares of worth $19.81 million while later fund manager owns 2.38 shares of worth $19.2 million as of Feb 28, 2025, which makes it owner of about 1.55% of company’s outstanding stock.
